R Court1, M T Chirehwa1, L Wiesner1, N de Vries2, J Harding3, T Gumbo4, G Maartens1, H McIlleron1. 1. Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town. 2. Brooklyn Chest Hospital, Cape Town. 3. DP Marais Hospital, Cape Town, South Africa. 4. Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, TX, USA.
Abstract
SETTING: Treatment outcomes in multidrug-resistant tuberculosis (MDR-TB) are poor. Due to drug toxicity and a long treatment duration, approximately half of patients are treated successfully. Medication is often crushed for patients who have difficulty swallowing whole tablets. Whether crushing tablets affects drug exposure in MDR-TB treatment is not known.OBJECTIVE AND DESIGN: We performed a sequential pharmacokinetic study in patients aged >18 years on MDR-TB treatment at two hospitals in Cape Town, South Africa. We compared the bioavailability of pyrazinamide, moxifloxacin, isoniazid (INH), ethambutol and terizidone when the tablets were crushed and mixed with water before administration vs. swallowed whole. We sampled blood at six time points over 10 h under each condition separated by 2 weeks. Non-compartmental analysis was used to derive the key pharmacokinetic measurements. RESULTS: Twenty participants completed the study: 15 were men, and the median age was 31.5 years. There was a 42% reduction in the area under the curve AUC0-10 of INH when the tablets were crushed compared with whole tablets (geometric mean ratio 58%; 90%CI 47-73). Crushing tablets of pyrazinamide, moxifloxacin, ethambutol and terizidone did not affect the bioavailability significantly. CONCLUSION: We recommend that crushing of INH tablets in the MDR-TB treatment regimen be avoided. Paediatric INH formulations may be a viable alternative if the crushing of INH tablets is indicated.
SETTING: Treatment outcomes in multidrug-resistant tuberculosis (MDR-TB) are poor. Due to drug toxicity and a long treatment duration, approximately half of patients are treated successfully. Medication is often crushed for patients who have difficulty swallowing whole tablets. Whether crushing tablets affects drug exposure in MDR-TB treatment is not known.OBJECTIVE AND DESIGN: We performed a sequential pharmacokinetic study in patients aged >18 years on MDR-TB treatment at two hospitals in Cape Town, South Africa. We compared the bioavailability of pyrazinamide, moxifloxacin, isoniazid (INH), ethambutol and terizidone when the tablets were crushed and mixed with water before administration vs. swallowed whole. We sampled blood at six time points over 10 h under each condition separated by 2 weeks. Non-compartmental analysis was used to derive the key pharmacokinetic measurements. RESULTS: Twenty participants completed the study: 15 were men, and the median age was 31.5 years. There was a 42% reduction in the area under the curve AUC0-10 of INH when the tablets were crushed compared with whole tablets (geometric mean ratio 58%; 90%CI 47-73). Crushing tablets of pyrazinamide, moxifloxacin, ethambutol and terizidone did not affect the bioavailability significantly. CONCLUSION: We recommend that crushing of INH tablets in the MDR-TB treatment regimen be avoided. Paediatric INH formulations may be a viable alternative if the crushing of INH tablets is indicated.
Authors: Stephanie Thee; Anthony J Garcia-Prats; Heather R Draper; Helen M McIlleron; Lubbe Wiesner; Sandra Castel; H Simon Schaaf; Anneke C Hesseling Journal: Clin Infect Dis Date: 2014-10-30 Impact factor: 9.079
Authors: Emmanuel Chigutsa; Jotam G Pasipanodya; Marianne E Visser; Paul D van Helden; Peter J Smith; Frederick A Sirgel; Tawanda Gumbo; Helen McIlleron Journal: Antimicrob Agents Chemother Date: 2014-10-13 Impact factor: 5.191
Authors: R Court; L Wiesner; A Stewart; N de Vries; J Harding; G Maartens; T Gumbo; H McIlleron Journal: Int J Tuberc Lung Dis Date: 2018-01-01 Impact factor: 2.373
Authors: J J Furin; C D Mitnick; S S Shin; J Bayona; M C Becerra; J M Singler; F Alcantara; C Castañieda; E Sanchez; J Acha; P E Farmer; J Y Kim Journal: Int J Tuberc Lung Dis Date: 2001-07 Impact factor: 2.373
Authors: Jennifer J Kiser; Rui Zhu; David Z DʼArgenio; Mark F Cotton; Raziya Bobat; George D McSherry; Shabir A Madhi; Vincent J Carey; Heiner I Seifart; Cedric J Werely; Courtney V Fletcher Journal: Ther Drug Monit Date: 2012-08 Impact factor: 3.681
Authors: Petros Isaakidis; Bhanumati Varghese; Homa Mansoor; Helen S Cox; Joanna Ladomirska; Peter Saranchuk; Esdras Da Silva; Samsuddin Khan; Roma Paryani; Zarir Udwadia; Giovanni Battista Migliori; Giovanni Sotgiu; Tony Reid Journal: PLoS One Date: 2012-07-11 Impact factor: 3.240
Authors: Maxwell T Chirehwa; Richard Court; Mariana de Kock; Lubbe Wiesner; Nihal de Vries; Joseph Harding; Tawanda Gumbo; Gary Maartens; Rob Warren; Paolo Denti; Helen McIlleron Journal: Antimicrob Agents Chemother Date: 2020-10-20 Impact factor: 5.191
Authors: Maxwell T Chirehwa; Richard Court; Mariana de Kock; Lubbe Wiesner; Nihal de Vries; Joseph Harding; Tawanda Gumbo; Gary Maartens; Rob Warren; Paolo Denti; Helen McIlleron Journal: Antimicrob Agents Chemother Date: 2021-07-26 Impact factor: 5.191
Authors: Francisco Beraldi-Magalhaes; Suzanne L Parker; Cristina Sanches; Leandro Sousa Garcia; Brenda Karoline Souza Carvalho; Mariana Millan Fachi; Marcus Vinicius de Liz; Roberto Pontarolo; Jeffrey Lipman; Marcelo Cordeiro-Santos; Jason A Roberts Journal: Antibiotics (Basel) Date: 2021-12-20